Site icon Market Globalist

Is that why Addex Therapeutics (ADXN) shares dropped earlier this morning?

TDOC Stock

A biotech firm, Addex Therapeutics Ltd (Nasdaq: ADXN), shares melted in the premarket as ‎it dropped -21.23% to $10.23 after it revealed the pricing of an underwritten public offering ‎of 6,000,000 shares at a price of approximately CHF1.47 per share or $10 per ADS. ADS ‎represents the right to receive six shares of Addex. Before deducting underwriter discounts ‎and commissions, Addex expects gross proceeds from the offering to reach $10 million. The ‎offering is likely to close on or about January 11, 2021, provided all closing conditions are ‎satisfied.‎

Get the hottest stocks to trade every day ‎before the market opens 100% ‎free. Click here now. 

The sole book-running manager for the offering is H.C. Wainwright & Co.‎

Discover Tomorrow's Stocks Today!

When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.

Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored

Addex has licensed the underwriter up to 900,000 additional shares for 30 days at the public ‎offering price, less underwriting discounts, and com, missions.‎

Read More

Addex will issue the New Shares from its authorized share capital without granting the ‎existing shareholders any preemptive rights.‎

It is expected that the New Shares if issued, will be listed on the SIX Swiss Exchange. The ‎New Shares will rank pari passu to Addex’s existing shares.‎